cytochrome P450 family 2 subfamily A member 13Genealiases: CPAD · CYP2A · CYPIIA13
Q-omics provides the consensus-scored CYP2A13 profile across patient tissues and cancer cell-line models. CYP2A13 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, CYP2A13 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, CYP2A13 RNA expression shows 8,398 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CESC, LUSC, and TGCT as cancer lineages where CYP2A13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP2A13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP2A13 survival associations across molecular data types. CYP2A13 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP2A13 RNA expression–survival associations across cancer types. High CYP2A13 expression shows unfavorable associations in KICH, CHOL, COAD and SCLC, but favorable associations in CESC and LUAD. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify CESC as the clearest survival context for CYP2A13 RNA expression.
This table summarizes CYP2A13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP2A13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP2A13 shows lower tumor expression in LUSC, CHOL, LUAD and COAD and higher tumor expression in BRCA and ESCA. The LUSC box plot shows higher CYP2A13 RNA expression in normal versus tumor tissue (log2 FC = −0.754, t-test p < 0.001).
This table shows molecular features associated with CYP2A13 in patient tissues and cancer cell lines. In patient samples, CYP2A13 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP2A13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
